JGBs Consolidate Ahead of Finance Ministry's 10-Year Auction
0020 GMT — JGBs consolidate in the morning Tokyo session ahead of the Japanese Finance Ministry's auction today of 2.6 trillion yen in 10-year government bonds. 'Tariff uncertainty could sap auction bids from some quarters,' SMBC Nikko Securities' Miki Den says in a research report. However, the Bank of Japan's dovish posturing has probably led to many investors trimming their outlook on JGB yields, so the auction is expected to 'clear smoothly,' the senior Japan rates strategist adds. The 10-year JGB yield is down 0.5bps at 1.290%. (ronnie.harui@wsj.com)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
Business Wire
an hour ago
- Business Wire
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. 'This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe,' said Perry Sternberg, Chief Executive Officer of Sydnexis. 'This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention.' The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. 'The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study,' said Patrick Johnson, Ph.D., President of Sydnexis. 'This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date.' Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. 'As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic,' said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. 'The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide.' About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital.
Yahoo
2 hours ago
- Yahoo
India plans rare earth magnet incentives as supply threat mounts, sources say
By Aditi Shah, Neha Arora and Aditya Kalra NEW DELHI (Reuters) -India is holding talks with companies to establish long-term stockpiles of rare earth magnets by offering fiscal incentives for domestic production, people familiar with the matter said. Building such a supply chain could take years, but would reduce India's dependence on shipments from China, which sent shockwaves across global industries, particularly autos, with its April 4 move to curb exports of rare earth materials. China controls 90% of the processing of such magnets, also used in industries such as clean energy and defence. Now Prime Minister Narendra Modi's government wants to develop domestic manufacturing capabilities and is considering offering production-based fiscal incentives to companies, said two sources who sought anonymity as the talks are private. The scheme, being drafted by the ministry of heavy industries, also envisions partly funding the difference between the final price of the made-in-India magnet and the cost of the Chinese imports, the first source said. This would help achieve cost parity and boost local demand, the source said, adding that funding for the scheme has yet to be decided, with the government likely to meet industry officials next week to finalise the details. The heavy industries ministry did not respond to Reuters' queries. Although a state-run firm, IREL, has been mining rare earth materials for years, these are mainly used by the atomic energy and defence units, with most supplies for other uses still imported from China. India's move comes as auto companies the world over flag risks that they could face supply disruptions within days. In Japan, Suzuki Motor, has suspended production of its Swift car because of China's curbs. In India, auto industry body SIAM has privately told the government it expects production "to come to a grinding halt" within a timeframe starting from the end of May or early June. The heavy industries ministry also plans to send a delegation of auto industry executives to meet officials in Beijing to push for faster approvals, with two industry officials warning that was the only near-term solution. "The short-term solution has to be to get Chinese authorities to clear things," said one of the executives, who fears shortages at his company. "A radical shift in supply chain is not possible in the short term." Some auto companies and their suppliers will be able to stretch operations until the end of June, after which the situation will turn "really scary", said the second executive, adding it would affect not just electric cars but all vehicles. India has the world's third-largest reserves of rare earths of 6.9 million tons, the U.S. Geological Survey says, but only mines a fraction because private companies make limited investments. A government campaign launched in April, the National Critical Mineral Mission, aims to attain self-reliance in the sector. In recent years, it has begun exploration for neodymium, a rare earth widely used in magnets for the auto industry. India also exports neodymium to Japan for lack of domestic processing capability, two of the sources said. Commercially available export data showed India exported nearly $7 million worth of the rare earth material to Toyota Tsusho between January and April. This week, Modi's office discussed the impact of the magnet crisis on the small but fast-growing EV sector, to which investors have committed billions of dollars, a person familiar with the talks said. It also weighed the possibility of tariff exemptions for imports of machines required by domestic manufacturers, the source said, adding, "The government is looking into it critically. They are serious."
